FrancophonIA/ELRC3.0 huggingface dataset:
English: The efficacy of dasabuvir has not been established in patients with HCV genotypes other than genotype 1; Exviera should not be used for the treatment of patients infected with other genotypes than
Swedish: Effekt för dasabuvir har inte fastställts hos patienter med andra HCV-genotyper än genotyp 1.
English: Marketing Authorisation Holder AbbVie Ltd
Swedish: INNEHAVARE AV GODKÄNNANDE FÖR FÖRSÄLJNING AbbVie Ltd
English: The majority of these ALT elevations were transient and assessed as related to Exviera and ombitasvir/paritaprevir/ritonavir.
Swedish: Merparten ALAT-stegringar var övergående och bedömdes vara relaterat till Exviera och ombitasvir/paritaprevir/ritonavir.
English: Target Emergent amino acid substitutionsa
Swedish: Nyuppkomna aminosyrasubstitutioner a
English: Mechanism: CYP3A4/Pgp inhibition by ketoconazole and paritaprevir/ ritonavir/ ombitasvir
Swedish: Mekanism: CYP3A4/Pgp-hämning av ketokonazol och paritaprevir/ ritonavir/ ombitasvir
English: PEARL-II was a randomised, global multicentre, open-label trial conducted in 179 adults with chronic genotype 1b hepatitis C virus infection without cirrhosis who did not achieve SVR with prior treatment with pegIFN/RBV.
Swedish: PEARL-II var en randomiserad, global multicenter, öppen studie gjord på 179 vuxna med kronisk hepatit C-virusinfektion genotyp 1b utan cirros som inte uppnådde SVR med tidigare behandling med pegIFN/RBV.
English: Tacrolimus 2 mg was dosed alone and 2 mg was administered with Exviera + ombitasvir/paritaprevir/ritonavir.
Swedish: Takrolimus 2 mg ensamt och 2 mg administrerat med Exviera + ombitasvir/paritaprevir/ritonavir.
English: The majority of adverse reactions presented in Table 3 were of grade 1 severity in Exviera- and ombitasvir/paritaprevir/ritonavir-containing regimens.
Swedish: Merparten av biverkningarna som anges i Tabell 3 hade svårhetgrad 1 vid behandlingen med Exviera och ombitasvir/paritaprevir/ritonavir.
English: Mechanism: CYP3A4 induction by enzalutamide or mitotane.
Swedish: Mekanism: CYP3A4induktion av enzalutamid eller mitotan.
English: Hepatobiliary Disorders: Hepatic decompensation, hepatic failure have been observed during treatment with Exviera with ombitasvir/paritaprevir/ritonavir, with or without ribavirin (see section 4.4).
Swedish: Biverkningar som rapporterats efter att produkten släppts ut på marknaden Lever och gallvägar: Leverdekompensation, leversvikt har observerats vid behandling med Exviera med ombitasvir/paritaprevir/ritonavir, med eller utan ribavirin (se avsnitt 4.4).
English: ANTICOAGULANTS Warfarin
Swedish: ANTIKOAGULANTIA Warfarin Exviera +
English: The M1 metabolite of dasabuvir had EC50 values of 39 and 8 nM against genotype 1a-H77 and 1bCon1 strains in HCV replicon cell culture assays, respectively, and the activity of the M1 metabolite was attenuated 3- to 4-fold in the presence of 40% human plasma.
Swedish: Dasabuvirs metabolit M1 hade EC50-värden på 39 respektive 8 nM mot genotyp 1a-H77 och 1bCON1 stammar i HCV replikoncellsanalysen.
English: Arm A: Exviera and ombitasvir/paritaprevir/ritonavir + RBV Arm B: Exviera and ombitasvir/paritaprevir/ritonavir
Swedish: Arm A: Exviera och ombitasvir/paritaprevir/ritonavir + RBV Arm B: Exviera och ombitasvir/paritaprevir/ritonavir
English: Arm A: Exviera and ombitasvir/paritaprevir/ritonavir + RBV Arm B: Placebo
Swedish: Arm A: Exviera och ombitasvir/paritaprevir/ritonavir + RBV Arm B: Placebo
English: Subjects randomised to the placebo arm received placebo for 12 weeks, after which they received open-label Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin for 12 weeks.
Swedish: Patienter som randomiserats till placeboarmen fick placebo i 12 veckor, därefter fick de öppen behandling med Exviera och ombitasvir/paritaprevir/ritonavir i kombination med ribavirin i 12 veckor.
English: No dose adjustment needed for Exviera + ombitasvir/paritaprevir/
Swedish: Ingen dosjustering krävs för Exviera + ombitasvir/paritaprevir/
English: SAPPHIRE-II was a randomised, global multicentre, double-blind, placebo-controlled trial conducted in 394 subjects with genotype 1 chronic hepatitis C virus infection without cirrhosis who did not achieve SVR with prior treatment with pegIFN/RBV.
Swedish: SAPPHIRE II var en randomiserad, global multicenter, dubbelblind, placebokontrollerad studie gjord på 394 patienter med kronisk HCV-infektion genotyp 1 utan cirros som inte uppnådde SVR med tidigare behandling med pegIFN/RBV.
English: Mechanism: OATP1B/BC RP inhibition by paritaprevir.
Swedish: Mekanism: OATP1B/B CRP hämning av paritaprevir
English: In subjects receiving Exviera and ombitasvir/paritaprevir/ritonavir without ribavirin, adverse events typically associated to ribavirin (e.g. nausea, insomnia, anaemia) were less frequent and no subjects (0/588) permanently discontinued treatment due to adverse reactions.
Swedish: Hos patienter som fick Exviera och ombitasvir/paritaprevir/ritonavir utan ribavirin, var biverkningar som vanligtvis förknippas med ribavirin (t.ex. illamående, sömnlöshet, anemi) mindre frekventa.
English: The recommended dose of darunavir is 800 mg once daily, without ritonavir, when administered at the same time as ombitasvir/paritaprevir/ ritonavir + dasabuvir (ritonavir dose in ombitasvir/paritaprevir/ ritonavir will provide darunavir pharmacokinetic enhancement).
Swedish: Mekanism: okänd ritonavir ombitasvir utan ritonavir, när det ges vid samma tidpunkt som ombitasvir/paritaprevir/riton avir + dasabuvir (ritonavirdosen i ombitasvir/paritaprevir/riton avir kommer att ge en förhöjning av darunavirs farmakokinetik).
English: Dose normalized cyclosporine ratios are shown for interaction with Exviera + ombitasvir/paritaprevir/ritonavir.
Swedish: Dosnormaliserad ciklosporinratio visas för interaktion med Exviera + ombitasvir/paritaprevir/ritonavir.
English: ANTICONVULSANTS carbamazepine
Swedish: ANTIEPILEPTIKA Karbamazepin
English: SAPPHIRE-I was a randomised, global multicentre, double-blind, placebo-controlled trial conducted in 631 treatment-naïve adults with genotype 1 chronic hepatitis C virus infection without cirrhosis.
Swedish: SAPPHIRE I var en randomiserad, global multicenter, dubbelblind, placebokontrollerad studie gjord på 631 behandlingsnaiva vuxna med kronisk HCV-infektion genotyp 1 utan cirros.
English: Subjects randomised to the placebo arm received placebo for 12 weeks, after which they received Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin for 12 weeks.
Swedish: Patienter som randomiserats till placeboarmen fick placebo i 12 veckor, därefter fick de Exviera och ombitasvir/paritaprevir/ritonavir i kombination med ribavirin i 12 veckor.
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV for 12 weeks n/N % 95% CI
Swedish: Exviera och ombitasvir/paritaprevir/ritonavir med RBV i 12 veckor n/N % 95 % KI
English: Phenytoin
Swedish: S-mefenytoin
English: Two patients discontinued Exviera and ombitasvir/paritaprevir/ritonavir due to elevated ALT, including one on ethinylestradiol.
Swedish: Två patienter avslutade behandlingen på grund av stegring i ALAT, inklusive en som använde etinylestradiol.
English: Subjects were randomised in a 1:1 ratio to receive Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks of treatment.
Swedish: Patienterna randomiserades i förhållandet 1:1 för att få behandling med Exviera och ombitasvir/paritaprevir/ritonavir med eller utan ribavirin i 12 veckor.
English: Arm A: Exviera and ombitasvir/paritaprevir/ritonavir + RBV
Swedish: Arm A: Exviera och ombitasvir/paritaprevir/ritonavir + RBV
English: Arm B: Exviera and ombitasvir/paritaprevir/ritonavir
Swedish: Arm B: Exviera och ombitasvir/paritaprevir/ritonavir
English: Subjects were randomised in a 1:2 ratio to receive Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks of treatment.
Swedish: Patienterna randomiserades i förhållandet 1:2 för att få behandling med Exviera och ombitasvir/paritaprevir/ritonavir med eller utan ribavirin i 12 veckor.
English: PEARL-IV was a randomised, global multicentre, double-blind, controlled trial conducted in 305 treatment-naïve adults with genotype 1a chronic hepatitis C virus infection without cirrhosis.
Swedish: PEARL IV var en randomiserad, global multicenter, dubbelblind, kontrollerad studie gjord på 305 behandlingsnaiva vuxna med kronisk HCV-infektion genotyp 1a utan cirros.
English: CYP2C8 inhibitor:
Swedish: CYP2C8hämning.
English: Arm B: Exviera and ombitasvir/paritaprevir/ritonavir + RBV (24 weeks)
Swedish: Arm B: Exviera och ombitasvir/paritaprevir/ritonavir + RBV (24 veckor)
English: Dose normalized tacrolimus ratios are shown for interaction with Exviera + ombitasvir/paritaprevir/ritonavir.
Swedish: Dosnormaliserad takrolimusratio visas för interaktion med Exviera + ombitasvir/paritaprevir/ritonavir.
English: Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin were administered for either 12 or 24 weeks of treatment.
Swedish: Behandling med Exviera och ombitasvir/paritaprevir/ritonavir i kombination med ribavirin administrerades i antingen 12 eller 24 veckor.
English: SVR12 for HIV-1 co-infected Subjects in TURQUOISE-I
Swedish: Tabell 16 SVR12 för patienter med samtidig HIV-1 infektion i TURQUOISE 1
English: PEARL-III was a randomised, global multicentre, double-blind, controlled trial conducted in 419 treatment-naïve adults with genotype 1b chronic hepatitis C virus infection without cirrhosis.
Swedish: PEARL III var en randomiserad, global multicenter, dubbelblind, kontrollerad studie gjord på 419 behandlingsnaiva vuxna med kronisk HCV-infektion genotyp 1b utan cirros.
English: Mechanism: Increase in paritaprevir exposures may be due to inhibition of
Swedish: Ökning av paritaprevir beror möjligen på
English: NAME OF THE MEDICINAL PRODUCT Exviera 250 mg film-coated tablets dasabuvir
Swedish: LÄKEMEDLETS NAMN Exviera 250 mg filmdragerade tabletter dasabuvir
English: Digoxin 0.5 mg single dose
Swedish: Alprazolam 0,5 mg enkeldos
English: Table 10 shows the SVR12 rates for treatment-experienced subjects with genotype 1-infection receiving Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin for 12 weeks in SAPPHIRE-II.
Swedish: Tabell 10 visar SVR12-resultat för behandlingserfarna patienter med genotyp 1-infektion som fick Exviera och ombitasvir/paritaprevir/ritonavir i kombination med ribavirin i 12 veckor i SAPPHIRE II.
English: r paritaprevir
Swedish: ↓ paritaprevir
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Inner carton of multipack of 14 film-coated tablets - without blue box
Swedish: UPPGIFTER SOM SKA FINNAS PÅ YTTRE FÖRPACKNINGEN Innerförpackning 14 filmdragerade tabletter
English: Ethinylestradiol containing oral contraceptives are contraindicated (see section 4.3).
Swedish: Etinylestradiol-innehållande orala preventivmedel är kontraindicerat (se avsnitt
English: CONTRACEPTIVES ethinylestradi ol/ norgestimate 0.035/0.25 m g once daily
Swedish: PREVENTIVMEDEL Etinylestradi ol/ norgestimat mg en gång dagligen
English: Arm A: Exviera and ombitasvir/paritaprevir/ritonavir + RBV (12 weeks)
Swedish: Arm A: Exviera och ombitasvir/paritaprevir/ritonavir + RBV (12 veckor)
English: IRON CHELATORS Deferasirox Exviera ombitas vir/parit aprevir/ ritonavi r
Swedish: JÄRNKELATKOMPLEXBILDARE Deferasirox Exviera + ombitasvir/ paritaprevir/ ritonavir
English: Table 8 shows the SVR12 rates for genotype 1b-infected, treatment-naïve subjects who received Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks in PEARL III.
Swedish: Tabell 8 visar SVR12-resultat för genotyp 1b-infekterade behandlingsnaiva patienter som fick Exviera och ombitasvir/paritaprevir/ritonavir med eller utan ribavirin i 12 veckor i PEARL III.
English: Table 7 shows the SVR12 rates for genotype 1-infected, treatment-naïve subjects receiving Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin for 12 weeks in SAPPHIRE-I.
Swedish: Tabell 7 visar SVR12-resultat för genotyp 1-infekterade behandlingsnaiva patienter som fick Exviera och ombitasvir/paritaprevir/ritonavir i kombination med ribavirin i 12 veckor i SAPPHIRE I.
English: Exviera and ombitasvir/paritaprevir/ritonavir were given for 12 weeks of treatment in combination with ribavirin.
Swedish: Behandling med Exviera och ombitasvir/paritaprevir/ritonavir gavs i 12 veckor i kombination med ribavirin.
English: Exviera is administered with ombitasvir/paritaprevir/ritonavir.
Swedish: Exviera administreras med ombitasvir/paritaprevir/ritonavir.
English: − Tablet core: microcrystalline cellulose (E460(i)), lactose monohydrate, copovidone,
Swedish: • Övriga innehållsämnen är: - Tablettkärna: mikrokristallin cellulosa (E460(i)), laktosmonohydrat, kopovidon, kroskarmellosnatrium, kolloidal kiseldioxid (E551), magnesiumstearat (E470b).
English: Treated subjects (N=419) had a median age of 50 years (range: 19 to 70); 45.8% were male; 4.8% were Black; 16.5% had a body mass index of at least 30 kg/m2; 9.3% had a history of depression or bipolar disorder; 79.0% had IL28B non-CC genotype; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Swedish: Behandlade patienter (N = 419) hade en medianålder på 50 år (intervall: 19-70), 45,8 % var män; 4,8 % var svarta; 16,5 % hade ett BMI på minst 30 kg/m2; 9,3 % hade en anamnes av depression eller bipolär sjukdom; 79,0 % hade IL28B icke-CC genotyp; 73,3 % hade baslinjenivåer av HCV-RNA på minst 800000 IE/ml; 20,3 % hade portal fibros (F2) och 10,0 % hade septal fibros (F3).
English: Table 11 shows the SVR12 rates for genotype 1b-infected, treatment-experienced subjects who received Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks in PEARL II.
Swedish: Tabell 11 visar SVR12-resultat för genotyp 1b-infekterade, behandlingserfarna patienter som fick Exviera och ombitasvir/paritaprevir/ritonavir med eller utan ribavirin i 12 veckor i PEARL II.
English: Caution should be used when sulfasalazine is co-administered with Exviera + ombitasvir/paritaprevir/ ritonavir.
Swedish: Försiktighet ska beaktas när sulfasalazin administreras samtidigt med Exviera + ombitasvir/ paritaprevir/ritonavir
English: Exviera and ombitasvir/paritaprevir/ritonavir for 12 weeks With RBV
Swedish: Exviera och ombitasvir/paritaprevir/ritonavir i 12 veckor Med RBV
English: If you forget to take Exviera
Swedish: Om du har tagit för stor mängd av Exviera
English: Transient elevations in serum bilirubin (predominantly indirect) were observed in subjects receiving Exviera and ombitasvir/paritaprevir/ritonavir with ribavirin, related to the inhibition of the bilirubin transporters OATP1B1/1B3 by paritaprevir and ribavirin-induced haemolysis.
Swedish: Övergående förhöjningar av serumbilirubin (främst okonjugerat) observerades hos patienter som fick Exviera och ombitasvir/paritaprevir/ritonavir med ribavirin, pga.
English: In subjects receiving Exviera and ombitasvir/paritaprevir/ritonavir with ribavirin, the most commonly reported adverse reactions (greater than 20% of subjects) were fatigue and nausea.
Swedish: De vanligaste rapporterade biverkningarna (mer än 20 % av patienterna) hos personer som fick Exviera och ombitasvir/paritaprevir/ritonavir med ribavirin var trötthet och illamående.
English: Exviera and ombitasvir/paritaprevir /ritonavir + ribavirin
Swedish: Exviera och ombitasvir/paritaprevir/ ritonavir + ribavirin
English: Mechanism: Effect on tacrolimus is due to
Swedish: Mekanism: Påverkan på takrolimus beror på CYP3A4
English: Treated subjects (N=631) had a median age of 52 years (range: 18 to 70); 54.5% were male; 5.4% were Black; 16.2% had a body mass index of at least 30 kg/m2; 15.2% had a history of depression or bipolar disorder; 69.3% had IL28B non-CC genotype; 79.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 15.4% had portal fibrosis (F2) and 8.7% had bridging fibrosis (F3); 67.7% had HCV genotype 1a infection; 32.3% had HCV genotype 1b infection.
Swedish: Behandlade patienter (N = 631) hade en medianålder på 52 år (intervall: 18 -70); 54,5 % var män; 5,4 % var svarta; 16,2 % hade ett BMI på minst 30 kg/m2; 15,2 % hade en anamnes av depression eller bipolär sjukdom; 69,3 % hade IL28B icke-CC genotyp; 79,1 % hade baslinjenivåer av HCV RNA på minst 800000 IE/ml; 15,4 % hade portal fibros (F2) och 8,7 % hade septal fibros (F3); 67,7 % hade HCV-infektion genotyp 1a; 32,3 % hade HCV-infektion genotyp 1b.
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV 24-week arm
Swedish: Exviera och ombitasvir/paritaprevir/ritonavir med RBV 24-veckor arm
English: In subjects with all three favourable baseline laboratory values (AFP < 20 ng/mL, platelets ≥ 90 x 109/L, and albumin ≥ 35 g/L), relapse rates were similar in subjects treated for 12 or 24 weeks.
Swedish: Hos patienter med alla tre fördelaktiga laboratorievärden (AFP <20 ng/ml, trombocyter ≥ 90 x 109/l,
English: Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 28.4% had a body mass index of at least 30 kg/m2; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 81.8% had IL28B non-CC genotype; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Swedish: Behandlade patienter (N = 380) hade en medianålder på 58 år (intervall: 21-71); 42,1 % var behandlingsnaiva, 36,1 % hade tidigare utebliven respons med pegIFN/RBV; 8,2 % hade tidigare partiell respons med pegIFN/RBV, 13,7 % hade tidigare recidiv pegIFN/RBV; 70,3 % var män; 3,2 % var svarta; 28,4 % hade ett BMI på minst 30 kg/m2; 14,7 % hade trombocytantal under 90 x 109/l; 49,7 % hade ett albuminvärde under 40 g/l; 86,1 % hade baslinjenivåer av HCV RNA på minst 800000 IE/ml; 81,8 % hade IL28B icke-CC genotyp; 24,7 % hade en anamnes av depression eller bipolär sjukdom; 68,7 % hade HCV genotyp 1a, 31,3 % hade HCV genotyp 1b.
English: Mechanism: OATP1B1 inhibition by paritaprevir.
Swedish: Mekanism: OATP1Bhämning av paritaprevir
English: Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders; and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; 21.8% had a body mass index of at least 30 kg/m2; 12.8% had a history of depression or bipolar disorder; 90.5% had IL28B non-CC genotype; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Swedish: Behandlade patienter (N = 179) hade en medianålder på 57 år (intervall: 26-70); 35,2 % hade tidigare utebliven respons med pegIFN/RBV; 28,5 % hade tidigare partiell respons med pegIFN/RBV, och 36,3 % hade tidigare recidiv med pegIFN/RBV; 54,2 % var män; 3,9 % var svarta; 21,8 % hade ett BMI på minst 30 kg/m2; 12,8 % hade en anamnes av depression eller bipolär sjukdom; 90,5 % hade IL28B icke-CC genotyp; 87,7 % hade baslinjenivåer av HCV RNA på minst 800000 IE/ml; 17,9 % hade portal fibros (F2) och 14,0 % hade septal fibros (F3).
English: ↔ ethinyl estradiol
Swedish: KG Knollstrasse
English: Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin was given for 12 weeks of treatment.
Swedish: Behandling med Exviera och ombitasvir/paritaprevir/ritonavir i kombination med ribavirin gavs i 12 veckor.
English: No dose adjustment is necessary for buprenorphine/naloxon e and Exviera + ombitasvir/paritaprevir/ ritonavir.
Swedish: Ingen dosjustering krävs för buprenorfin/naloxon och Exviera + ombitasvir/paritaprevir/riton avir.
English: Mechanism: possibly due to UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Swedish: Mekanism: Troligtvis UGThämning av paritaprevir, ombitasvir
English: Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 19.8% had a body mass index of at least 30 kg/m2; 20.6% had a history of depression or bipolar disorder; 89.6% had IL28B non-CC genotype; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Swedish: Behandlade patienter (N = 394) hade en medianålder på 54 år (intervall: 19-71); 49,0 % hade tidigare utebliven respons med pegIFN/RBV; 21,8 % hade tidigare partiell respons med pegIFN/RBV, och 29,2 % hade tidigare recidiv med pegIFN/RBV; 57,6 % var män; 8,1 % var svarta; 19,8 % hade ett BMI på minst 30 kg/m2; 20,6 % hade en anamnes av depression eller bipolär sjukdom; 89,6 % hade IL28B icke CC genotyp; 87,1 % hade baslinjenivåer av HCV RNA på minst 800000 IE per ml; 17,8 % hade portal fibros (F2) och 14,5 % hade septal fibros (F3); 58,4 % hade HCV-infektion genotyp 1a; 41,4 % hade HCV-infektion genotyp 1b.
English: Mechanism: CYP3A4 induction by St. John's Wort.
Swedish: CYP3A4induktion av johannesört.
English: No dose adjustment is necessary for norethindrone or Exviera + ombitasvir/paritaprevir/ ritonavir.
Swedish: Ingen dosjustering krävs för noretisteron eller Exviera + ombitasvir/paritaprevir/ ritonavir.
English: No dose adjustment is necessary for raltegravir or Exviera + ombitasvir/paritaprevir/ ritonavir.
Swedish: Ingen dosjustering krävs för raltegravir eller Exviera + ombitasvir/paritaprevir/riton avir.
English: Emtricitabine/ tenofovir 200 mg once daily/300 mg once daily
Swedish: 200 mg en gång dagligen/ 300 mg en gång om dagen ritonavir
English: This is due to liver function
Swedish: Nedsatt njurfunktion
English: Clinical Comments possibly due to UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Swedish: Mekanism: Troligtvis UGT1A1 hämning av paritaprevir, ombitasvir och dasabuvir.
English: No dose adjustment needed for dolutegravir when administered with Exviera + ombitasvir/paritaprevir/ ritonavir.
Swedish: Ingen dosjustering krävs för dolutegravir vid administrering med Exviera + ombitasvir/paritaprevir/ ritonavir.
English: NA No dose adjustment is necessary for paracetamol when administered with Exviera + ombitasvir/paritaprevir/ ritonavir.
Swedish: NA Ingen dosjustering krävs för paracetamol vid administrering med Exviera + ombitasvir/ paritaprevir/ritonavir.
English: Exviera ombitas vir/parit aprevir/ ritonavi r atazanavir
Swedish: Exviera + ombitasvir/ paritaprevir /ritonavir atazanavir
English: NA No dose adjustment needed for sofosbuvir when administered with Exviera + ombitasvir/paritaprevir /ritonavir.
Swedish: NA Ingen dosjustering krävs för sofosbuvir vid administrering med Exviera + ombitasvir/paritaprevir/ ritonavir.
English: Atazanavir/ ritonavir 300/100 mg once daily
Swedish: Lopinavir/ ritonavir 400/100 mg två gånger dagligen
English: NA No dose adjustment needed for abacavir or lamivudine when administered with Exviera + ombitasvir/paritaprevir/ ritonavir.
Swedish: NA Ingen dosjustering krävs för abakavir eller lamivudin vid administrering med Exviera + ombitasvir/paritaprevir/ ritonavir.
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV 12 weeks
Swedish: Exviera och ombitasvir/paritaprevir/ritonavir med RBV 12 veckor
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV 12-week arm
Swedish: Exviera och ombitasvir/paritaprevir/ritonavir med RBV 12-veckor arm
English: Mechanism: possibly due to UGT1A1 inhibition by paritaprevir, dasabuvir and ombitasvir and CYP3A4 inhibition by ritonavir
Swedish: Mekanism: Ökning av paritaprevirexponering kan bero på OATP1B1/ B3- och CYP3Ahämningen av atazanavir och
English: Adverse reactions identified with Exviera in combination with ombitasvir/paritaprevir/ritonavir or ombitasvir/paritaprevir/ritonavir and ribavirin
Swedish: Biverkningar identifierade med Exviera i kombination med ombitasvir/paritaprevir/ritonavir med och utan ribavirin